Zydus Cadila gets USFDA nod to mineral supplement Potassium Chloride ER Tablets
Ahmedabad: Drugmaker, Zydus Cadila recently announced that the company has received final approval from the US Food & Drug Administration( USFDA) to market Potassium Chloride Extended-Release Tablets, a mineral supplement used to treat or prevent low amounts of potassium in the blood. ...
Ahmedabad: Drugmaker, Zydus Cadila recently announced that the company has received final approval from the US Food & Drug Administration( USFDA) to market Potassium Chloride Extended-Release Tablets, a mineral supplement used to treat or prevent low amounts of potassium in the blood. The product in the strengths of 10 mEq (750 mg) and 20 mEq (1500 mg) will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 301 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Read also: Zydus Cadila cancer treatment injection Doxorubicin Hydrochloride Liposome gets USFDA okay
Zydus Cadila is a global pharmaceutical company headquartered in Ahmedabad, India.
The company discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Read also: COVID-19 Vaccine: Zydus Cadila, Bharat Biotech in Phase II trial
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd